Tetrazoles Concept

subject area of

• A Bone-Seeking trans-Cyclooctene for Pretargeting and Bioorthogonal Chemistry: A Proof of Concept Study Using ^99mTc- and ¹⁷⁷Lu-Labeled Tetrazines  Journal Articles
• AT ₁ Receptor Antagonist Treatment Caused Persistent Arterial Functional Changes in Young Spontaneously Hypertensive Rats  Journal Articles
• Acute Precipitants of Congestive Heart Failure Exacerbations  Journal Articles
• Adding candesartan-HCTZ to rosuvastatin increased adverse events but not benefits in patients at intermediate CV risk  Journal Articles
• Adherence to candesartan and placebo and outcomes in chronic heart failure in the CHARM programme: double-blind, randomised, controlled clinical trial  Journal Articles
• Age-Related Characteristics and Outcomes of Patients With Heart Failure With Preserved Ejection Fraction  Journal Articles
• Albuminuria in chronic heart failure: prevalence and prognostic importance  Journal Articles
• Antiplatelet Drugs  Journal Articles
• Assessment of Long-Term Effects of Irbesartan on Heart Failure With Preserved Ejection Fraction as Measured by the Minnesota Living With Heart Failure Questionnaire in the Irbesartan in Heart Failure With Preserved Systolic Function (I-PRESERVE) Trial  Journal Articles
• Association of Heart Rate and Outcomes in a Broad Spectrum of Patients With Chronic Heart Failure  Journal Articles
• Atrial Fibrillation and Risk of Clinical Events in Chronic Heart Failure With and Without Left Ventricular Systolic Dysfunction  Journal Articles
• Baseline Plasma NT-proBNP and Clinical Characteristics: Results From the Irbesartan in Heart Failure With Preserved Ejection Fraction Trial  Journal Articles
• Baseline characteristics and outcomes of patients with heart failure receiving bronchodilators in the CHARM programme  Journal Articles
• Benefits and safety of candesartan treatment in heart failure are independent of age: insights from the Candesartan in Heart failure--Assessment of Reduction in Mortality and morbidity programme  Journal Articles
• Blood-Pressure Lowering in Intermediate-Risk Persons without Cardiovascular Disease  Journal Articles
• Blood-Pressure and Cholesterol Lowering in Persons without Cardiovascular Disease  Journal Articles
• Body Mass Index and Prognosis in Patients With Chronic Heart Failure  Journal Articles
• Candesartan for the management of heart failure: more than an alternative  Journal Articles
• Candesartan in heart failure—assessment of reduction in mortality and morbidity (CHARM): Rationale and design  Journal Articles
• Catching Bubbles: Targeting Ultrasound Microbubbles Using Bioorthogonal Inverse‐Electron‐Demand Diels–Alder Reactions  Journal Articles
• Cephalosporin-induced hypoprothrombinemia: is the N-methylthiotetrazole side chain the culprit?  Journal Articles
• Characterization of health‐related quality of life in heart failure patients with preserved versus low ejection fraction in CHARM  Journal Articles
• Characterization of subgroups of heart failure patients with preserved ejection fraction with possible implications for prognosis and treatment response  Journal Articles
• Clinical Characteristics and Outcomes of Patients With Coronary Artery Disease and Angina  Journal Articles
• Clinical Characteristics and Outcomes of Young and Very Young Adults With Heart Failure  Journal Articles
• Clinical Correlates and Consequences of Anemia in a Broad Spectrum of Patients With Heart Failure  Journal Articles
• Clinical Outcomes According to Baseline Blood Pressure in Patients With a Low Ejection Fraction in the CHARM (Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity) Program  Journal Articles
• Clinical and Echocardiographic Characteristics and Cardiovascular Outcomes According to Diabetes Status in Patients With Heart Failure and Preserved Ejection Fraction  Journal Articles
• Clinical characteristics and outcomes of patients with angina and heart failure in the CHARM (Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity) Programme  Journal Articles
• Clinical outcomes according to QRS duration and morphology in the irbesartan in patients with heart failure and preserved systolic function (I‐PRESERVE) trial  Journal Articles
• Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial  Journal Articles
• Comparative impact of enalapril, candesartan or metoprolol alone or in combination on ventricular remodelling in patients with congestive heart failure  Journal Articles
• Comparison of Candesartan, Enalapril, and Their Combination in Congestive Heart Failure  Journal Articles
• Contribution of cardiac and extra‐cardiac disease burden to risk of cardiovascular outcomes varies by ejection fraction in heart failure  Journal Articles
• Cross-over study comparing effects of treatment with an angiotensin converting enzyme inhibitor and an angiotensin II type 1 receptor antagonist on cardiovascular changes in hypertension  Journal Articles
• Days alive and out of hospital and the patient journey in patients with heart failure: Insights from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program  Journal Articles
• Determinants of masked hypertension in hypertensive patients treated in a primary care setting  Journal Articles
• Developing and validating models to predict sudden death and pump failure death in patients with heart failure and preserved ejection fraction  Journal Articles
• Effect of Candesartan on Cause-Specific Mortality in Heart Failure Patients  Journal Articles
• Effect of a Leukotriene Antagonist, LY171883, on Cold Air-induced Bronchoconstriction in Asthmatics  Journal Articles
• Effect of candesartan on New York Heart Association functional classResults of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme  Journal Articles
• Effect of valsartan compared with valsartan/hydrochlorothiazide on plasma levels of cellular adhesion molecules: the Val-MARC trial  Journal Articles
• Effects of Candesartan on the Development of a New Diagnosis of Diabetes Mellitus in Patients With Heart Failure  Journal Articles
• Effects of Lipid‐Lowering and Antihypertensive Treatments in Addition to Healthy Lifestyles in Primary Prevention: An Analysis of the HOPE‐3 Trial  Journal Articles
• Effects of blood pressure and lipid lowering on cognition  Journal Articles
• Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial  Journal Articles
• Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial  Journal Articles
• Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial  Journal Articles
• Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme  Journal Articles
• Effects of enalapril, candesartan or both on neurohumoral activation and LV volumes and function in patients with heart failure not treated with a beta-blocker  Journal Articles
• Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138 769 individuals  Journal Articles
• Efficacy and safety of angiotensin receptor blockade are not modified by aspirin in patients with chronic heart failure: a cohort study from the Candesartan in Heart failure – Assessment of Reduction in Mortality and morbidity (CHARM) programme  Journal Articles
• Efficacy and safety of cilostazol based triple antiplatelet treatment versus dual antiplatelet treatment in patients undergoing coronary stent implantation: an updated meta-analysis of the randomized controlled trials  Journal Articles
• Efficacy and tolerability of adding an angiotensin receptor blocker in patients with heart failure already receiving an angiotensin‐converting inhibitor plus aldosterone antagonist, with or without a beta blocker. Findings from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)‐Added trial  Journal Articles
• Factors Associated With Outcome in Heart Failure With Preserved Ejection Fraction  Journal Articles
• Fluorous Analogue of Chloramine-T: Preparation, X-ray Structure Determination, and Use as an Oxidant for Radioiodination and s-Tetrazine Synthesis  Journal Articles
• HR 720, a novel angiotensin receptor antagonist inhibits the angiotensin II-induced trophic effects, fibronectin release and fibronectin-EIIIA+ expression in rat aortic vascular smooth muscle cells in vitro.  Journal Articles
• Heart failure with mid‐range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum  Journal Articles
• Heart failure with preserved ejection fraction: Clinical characteristics of 4133 patients enrolled in the I‐PRESERVE trial  Journal Articles
• Impact of Candesartan on Nonfatal Myocardial Infarction and Cardiovascular Death in Patients With Heart Failure  Journal Articles
• Impact of blood pressure lowering, cholesterol lowering and their combination in Asians and non-Asians in those without cardiovascular disease: an analysis of the HOPE 3 study  Journal Articles
• Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: An analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme  Journal Articles
• Impact of hospitalization for acute coronary events on subsequent mortality in patients with chronic heart failure  Journal Articles
• Improved radiosynthesis and preliminary in vivo evaluation of the 11C-labeled tetrazine [11C]AE-1 for pretargeted PET imaging  Journal Articles
• Incidence and Predictors of Hyperkalemia in Patients With Heart Failure  Journal Articles
• Influence of Ejection Fraction on Cardiovascular Outcomes in a Broad Spectrum of Heart Failure Patients  Journal Articles
• Influence of Nonfatal Hospitalization for Heart Failure on Subsequent Mortality in Patients With Chronic Heart Failure  Journal Articles
• Influence of Previous Heart Failure Hospitalization on Cardiovascular Events in Patients With Reduced and Preserved Ejection Fraction  Journal Articles
• Initial data supporting the design of the Candesartan in Heart failure — Assessment of Reduction in Mortality and morbidity (CHARM) programme  Journal Articles
• Initiation of sacubitril/valsartan in haemodynamically stabilised heart failure patients in hospital or early after discharge: primary results of the randomised TRANSITION study  Journal Articles
• International Geographic Variation in Event Rates in Trials of Heart Failure With Preserved and Reduced Ejection Fraction  Journal Articles
• Irbesartan in Patients with Atrial Fibrillation  Journal Articles
• Irbesartan in Patients with Heart Failure and Preserved Ejection Fraction  Journal Articles
• Leukotrienes, Airway Hyperresponsiveness, and Asthma  Journal Articles
• Long-term Effects of Statins, Blood Pressure-Lowering, and Both on Erectile Function in Persons at Intermediate Risk for Cardiovascular Disease: A Substudy of the Heart Outcomes Prevention Evaluation-3 (HOPE-3) Randomized Controlled Trial  Journal Articles
• Management of peripheral arterial disease in the elderly: focus on cilostazol  Journal Articles
• Mechanisms for perivascular adipose tissue-mediated potentiation of vascular contraction to perivascular neuronal stimulation: The role of adipocyte-derived angiotensin II  Journal Articles
• Mode of Death in Patients With Heart Failure and a Preserved Ejection Fraction  Journal Articles
• Modulation ofN-methyl-d-aspartate (NMDA) antagonist-induced darting behaviour by the peptidomimetic PAMTA  Journal Articles
• Monitoring the ACTIVE-W trial: Some issues in monitoring a noninferiority trial  Journal Articles
• Mortality and Morbidity Reduction With Candesartan in Patients With Chronic Heart Failure and Left Ventricular Systolic Dysfunction  Journal Articles
• Mortality predictors and effects of antithrombotic therapies in atrial fibrillation: insights from ACTIVE-W  Journal Articles
• Myocardial Infarction in Heart Failure With Preserved Ejection Fraction  Journal Articles
• Novel Approaches in Primary Cardiovascular Disease Prevention: The HOPE-3 Trial Rationale, Design, and Participants' Baseline Characteristics  Journal Articles
• Patient perception of the effect of treatment with candesartan in heart failure. Results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme  Journal Articles
• Peripheral arterial disease.  Journal Articles
• Peripheral arterial disease.  Journal Articles
• Periphere arterielle Verschlusskrankheit (PAVK)  Journal Articles
• Practical recommendations for the use of ACE inhibitors, beta‐blockers, aldosterone antagonists and angiotensin receptor blockers in heart failure: Putting guidelines into practice  Journal Articles
• Prevalence and Significance of Alterations in Cardiac Structure and Function in Patients With Heart Failure and a Preserved Ejection Fraction  Journal Articles
• Prevalence and prognostic impact of bundle branch block in patients with heart failure: Evidence from the CHARM programme  Journal Articles
• Prevalence and prognostic implications of electrocardiographic left ventricular hypertrophy in heart failure: evidence from the CHARM programme  Journal Articles
• Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program  Journal Articles
• Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: assessment of Reduction in Mortality and morbidity (CHARM) program.  Journal Articles
• Prior Pacemaker Implantation and Clinical Outcomes in Patients With Heart Failure and Preserved Ejection Fraction  Journal Articles
• Prognostic Value of Baseline Plasma Amino-Terminal Pro-Brain Natriuretic Peptide and Its Interactions With Irbesartan Treatment Effects in Patients With Heart Failure and Preserved Ejection Fraction  Journal Articles
• Prognostic Value of Insulin-Like Growth Factor-Binding Protein 7 in Patients with Heart Failure and Preserved Ejection Fraction  Journal Articles
• Prognostic importance of temporal changes in resting heart rate in heart failure patients: an analysis of the CHARM program  Journal Articles
• Randomized trial of candesartan cilexetil in the treatment of patients with congestive heart failure and a history of intolerance to angiotensin-converting enzyme inhibitors  Journal Articles
• Rationale and design of ACTIVE: The atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events  Journal Articles
• Reaching the therapeutic goal in hypertension: results from the Canadian valsartan observational study. (Diovantage 4).  Journal Articles
• Receptor subtypes mediating spinal cardiovascular effects of angiotensin II in rat using losartan and PD 123319  Journal Articles
• Red Cell Distribution Width as a Novel Prognostic Marker in Heart Failure  Journal Articles
• Relation of Peripheral Collagen Markers to Death and Hospitalization in Patients With Heart Failure and Preserved Ejection Fraction  Journal Articles
• Relationship Between Degree of Left Ventricular Dysfunction, Symptom Status, and Risk of Embolic Events in Patients With Atrial Fibrillation and Heart Failure  Journal Articles
• Relationship between heart rate and mortality and morbidity in the irbesartan patients with heart failure and preserved systolic function trial (I‐Preserve)  Journal Articles
• Relationship of dose of background angiotensin-converting enzyme inhibitor to the benefits of candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)–Added trial  Journal Articles
• Reliability, validity, and responsiveness of the six-minute walk test in patients with heart failure  Journal Articles
• Renal Function as a Predictor of Outcome in a Broad Spectrum of Patients With Heart Failure  Journal Articles
• Resource utilization and costs in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme  Journal Articles
• Risks and Benefits of Oral Anticoagulation Compared With Clopidogrel Plus Aspirin in Patients With Atrial Fibrillation According to Stroke Risk  Journal Articles
• Role of Renin-Angiotensin System Blockade in Patients With Diabetes Mellitus  Journal Articles
• Sex Differences in Clinical Characteristics and Outcomes in Elderly Patients With Heart Failure and Preserved Ejection Fraction  Journal Articles
• Sex Differences in Clinical Characteristics and Prognosis in a Broad Spectrum of Patients With Heart Failure  Journal Articles
• The CHARM program: the effects of candesartan for the management of patients with chronic heart failure  Journal Articles
• The CHARM programme  Journal Articles
• The Irbesartan in Heart Failure With Preserved Systolic Function (I-PRESERVE) Trial: Rationale and Design  Journal Articles
• The cost implication of primary prevention in the HOPE 3 trial  Journal Articles
• Usefulness of Temporal Changes in Neurohormones as Markers of Ventricular Remodeling and Prognosis in Patients With Left Ventricular Systolic Dysfunction and Heart Failure Receiving Either Candesartan or Enalapril or Both  Journal Articles
• Valsartan combined with clopidogrel and/or leflunomide for the treatment of progressive immunoglobulin A nephropathy  Journal Articles
• Valsartan, Captopril, or Both in Myocardial Infarction Complicated by Heart Failure, Left Ventricular Dysfunction, or Both  Journal Articles
• Weight loss and mortality risk in patients with chronic heart failure in the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme  Journal Articles
• Worsening Renal Function and Outcome in Heart Failure Patients With Preserved Ejection Fraction and the Impact of Angiotensin Receptor Blocker Treatment  Journal Articles
• Worsening renal function and outcome in heart failure patients with reduced and preserved ejection fraction and the impact of angiotensin receptor blocker treatment: data from the CHARM‐study programme  Journal Articles